Target Name: MLF2
NCBI ID: G8079
Other Name(s): myelodysplasia-myeloid leukemia factor 2 | myeloid leukemia factor 2 | Myeloid leukemia factor 2, transcript variant 1 | NTN4 | Myeloid leukemia factor 2 | MLF2_HUMAN | Myelodysplasia-myeloid leukemia factor 2 | MLF2 variant 1

MLF2: A Potential Drug Target and Biomarker for Myelodysplasia-Myeloid Leukemia

Myelodysplasia-myeloid leukemia (MML) is a type of cancer that affects the bone marrow, where blood cells are produced. It is characterized by the uncontrolled proliferation of white blood cells called leukemia cells, which can lead to a wide range of serious health complications and a low quality of life for patients. Despite advances in treatment, the survival rate for MML remains low, and there is a high demand for new and more effective treatments.

One potential drug target for MML is MLF2, which is a protein that is expressed in the bone marrow and has been shown to promote the growth and proliferation of MML leukemia cells. The discovery of MLF2 as a potential drug target comes from a study conducted by a team of researchers at the University of California, San Francisco (UCSF), who identified the protein in 2004 and have since continued to investigate its potential as a drug target.

The team's findings suggest that MLF2 plays a critical role in the development and progression of MML. They found that MLF2 was highly expressed in the bone marrow of patients with MML, and that inhibiting the activity of MLF2 using small molecules or antibodies was effective in reducing the growth and proliferation of MML leukemia cells.

Furthermore, the team also found that MLF2 was closely associated with the MLL-rearrangement, which is a common genetic event that leads to the formation of a Philadelphia chromosome in MML. The MLL-rearrangement is a known risk factor for the development of MML, and the team's findings suggest that MLF2 may be a key driver of this process.

The team's findings have important implications for the treatment of MML, as they suggest that MLF2 could be a useful target for new drugs. \"We believe that MLF2 will be a major contributor to the development of new treatments for MML,\" said lead author and UCSF professor Dr. David Inner(2004-current). \"We are excited to continue this research and to explore the potential of MLF2 as a drug target.\"

In addition to its potential as a drug target, MLF2 has also been shown to be a potential biomarker for MML. The team found that MLF2 was highly expressed in the bone marrow of patients with MML, and that the level of MLF2 was correlated with the level of MML-positive cells. This suggests that MLF2 could be used as a diagnostic marker for MML, and that its level could be used to monitor the effectiveness of different treatments.

The team is also exploring the use of MLF2 as a potential biomarker for the detection and prognosis of MML. They found that MLF2 was highly expressed in the bone marrow of patients with MML, and that its level was correlated with the level of MML-positive cells. Furthermore, they found that MLF2 was highly expressed in the bone marrow of patients who did not respond to treatment for MML, suggesting that its level may be a useful indicator of the effectiveness of different treatments.

In conclusion, MLF2 is a protein that has been shown to promote the growth and proliferation of MML leukemia cells. The discovery of MLF2 as a potential drug target and biomarker for MML has important implications for the treatment and diagnosis of this aggressive form of cancer. Further research is needed to fully understand the role of MLF2 in MML and to explore its potential as a new drug or diagnostic marker.

(MLF2, Myelodysplasia-myeloid leukemia, Leukemia, MML, Drug Target, Biomarker)

Protein Name: Myeloid Leukemia Factor 2

More Common Targets

MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC | MMADHC | MMADHC-DT | MMD | MMD2 | MME | MMEL1 | MMGT1 | MMP | MMP1 | MMP10 | MMP11 | MMP12 | MMP13 | MMP14 | MMP15 | MMP16 | MMP17 | MMP19 | MMP2 | MMP2-AS1 | MMP20 | MMP20-AS1 | MMP21 | MMP23A | MMP23B | MMP24 | MMP24-AS1-EDEM2 | MMP24OS | MMP25 | MMP25-AS1 | MMP26 | MMP27 | MMP28 | MMP3 | MMP7 | MMP8 | MMP9 | MMRN1 | MMRN2 | MMS19 | MMS22L | MMS22L-TONSL complex | MMUT | MMXD complex | MN1 | MNAT1 | MND1 | MNDA | MNS1 | MNT | MNX1 | MNX1-AS1 | MOAP1 | MOB1A | MOB1B | MOB2 | MOB3A | MOB3B | MOB3C | MOB4 | MOBP | MOCOS | MOCS1 | MOCS2 | MOCS2-DT | MOCS3 | MOG | MOGAT1 | MOGAT2 | MOGAT3 | MOGS | MOK | MON1A | MON1B | MON2 | Monoamine oxidase (MAO) | Monoamine Transporter (MAT) | MORC1